ArticleNPJ precision oncology2025
Identifying the crucial oncogenic mechanisms of DDX56 based on a machine learning-based integration model of RNA-binding proteins.
Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
RNA-binding proteins (RBPs) play a fundamental role in cellular metabolism, with their disturbance leading to large-scale transcriptomic dysregulation. RBP dysregulation is highly prevalent in human cancers; however, its role in lung adenocarcinoma (LUAD) has not been systematically investigated. To establish a more effective and robust risk model, a machine learning integration program was used to screen hub prognostic RBPs. Our risk model C-index performed extremely well among 103 published signatures. The high-risk group had a lower immune score and worse immunotherapy effects. As one of the members of the RNA helicase family, DDX56 can interact with certain transcription factors, thereby regulating the expression of its downstream targets. DDX56 exerts an anti-apoptotic effect and reduces the sensitivity to carboplatin treatment by promoting Bcl-2 transcription in LUAD cells. Additionally, DDX56 activates NF-kB signaling pathways, which may be related to DDX56-mediated promotion of Bcl-2 transcription, proliferation, migration, and invasion in LUAD patients.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.